Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegsunercept Extended Treatment in Rheumatoid Arthritis
NCT00111423Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2002
- Modality
- PEGylated Peptides, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of pegsunercept in rheumatoid arthritis (RA), sponsored by Amgen. Started Aug 2002; status: completed.
02
Drugs
pegsunercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00111423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111423.